Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2020-05-28 18:29:38
Reporting Period:
Accepted Time:
2020-05-28 18:29:38
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1082038 Durect Corp DRRX Pharmaceutical Preparations (2834) 943297098
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1781002 Bleichroeder Lp 1345 Avenue Of The Americas
47Th Floor
New York NY 10105
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-05-26 39,388 $2.50 26,664,656 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
  1. The transaction reported herein was entered into in error. In addition, the sale by the reporting person of 39,388 shares of Issuer's common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the purchase by the reporting person of 39,388 shares of the Issuer's common stock on February 6, 2020 as reported in a prior Form 4 filing. Pursuant to a settlement agreement with the Issuer, the reporting person has paid to the issuer $34,588.00, representing the full amount of the profit realized in connection with the short-swing transaction.
  2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions. Prices ranged from $2.50 to $2.511 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. This form is filed by Bleichroeder LP. Bleichroeder LP serves as registered investment adviser to 21 April Fund, Ltd., 21 April Fund, LP and other managed accounts that directly hold these securities. Bleichroeder LP disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that Bleichroeder LP is the beneficial owner of the securities for purposes of Section 16 or for any other purposes. 21 April Fund, Ltd. owns 16,036,514 shares and 21 April Fund, LP owns 4,718,700 shares respectively of these 26,664,656 shares reported in this form.